I agree whole-heartedly with Mike Wokasch's comments on industry views of Merck's CEO Ken Frazer staying the course with R&D spending. I do think it is consistent with Merck's mission to remain a leading supplier of innovative medicines that are clinically effective and differentiated -- and that can prove their value.
See post from Pharma Reform blog.
Let the view from the cheap seats from analysts who are interested in short-term financial results be damned. AMEN.
Posted by Bruce Lehr Dec 16th 2011.